Ion Asset Management Ltd. Has $807.77 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Ion Asset Management Ltd. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,650,000 shares of the company's stock after buying an additional 409,778 shares during the quarter. Teva Pharmaceutical Industries comprises 47.0% of Ion Asset Management Ltd.'s portfolio, making the stock its largest position. Ion Asset Management Ltd. owned about 3.24% of Teva Pharmaceutical Industries worth $807,766,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. Finally, IFP Advisors Inc raised its holdings in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the subject of a number of research reports. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.60 during mid-day trading on Friday, reaching $16.22. 11,919,719 shares of the stock were exchanged, compared to its average volume of 9,965,640. The company has a market cap of $18.39 billion, a price-to-earnings ratio of -11.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm has a 50-day simple moving average of $15.11 and a 200 day simple moving average of $17.51. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.